TheraRadar
← Back
Data updated: Mar 29, 2026

CADILA

CardiovascularNeurologyOphthalmology
Generics

CADILA is a generic drug manufacturer focused on Cardiovascular, Neurology, Ophthalmology.

2016
Since
11
Drugs
-
Trials
130
Approved (2yr)

Key Drugs

No active drugs

Top Drug Revenues Pro

Loading...

Revenue Over Time Pro

Loading...

Recent Activity

METRONIDAZOLE 2026-02-17
Labeling
METRONIDAZOLE 2026-02-17
Labeling
METRONIDAZOLE 2026-02-13
ACYCLOVIR 2026-01-22
Labeling
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE 2026-01-21
ACETAZOLAMIDE 2026-01-12
Labeling
ACETAZOLAMIDE 2026-01-08
Labeling
ACETAZOLAMIDE 2026-01-08
Labeling
SEC Filings Pro
Loading...

Therapeutic Areas

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Cardiovascular 52%
4 drugs
Neurology 13%
1 drugs
Ophthalmology 13%
1 drugs
Infectious Disease 13%
1 drugs
Immunology 9%
0 drugs Phase 3: 1

Pipeline Forecast

Loading...

Upcoming Trial Milestones Pro

Loading...

Patent Cliff Pro

Loading...

Competitors by Therapeutic Area

AbbVie big-pharma
Immunology, Neurology, Infectious Disease, Ophthalmology
Novartis big-pharma
Cardiovascular, Immunology, Ophthalmology
BAUSCH AND LOMB specialty
Ophthalmology, Cardiovascular, Infectious Disease, Immunology
Merck big-pharma
Infectious Disease, Cardiovascular, Immunology
Baxter specialty
Infectious Disease, Cardiovascular, Ophthalmology